H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Zynex (ZYXI – Research Report) today and set a price target of $20.00. The company’s shares opened today at $9.70.
According to TipRanks, Chen is an analyst with an average return of -31.5% and a 24.54% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, First Wave Bio, and Anixa Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zynex with a $22.00 average price target.
See the top stocks recommended by analysts >>
ZYXI market cap is currently $353M and has a P/E ratio of 21.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.
Read More on ZYXI:
